Alto Neuroscience Inc (ANRO)

$13.38 -0.01 (-0.07%)
Market Cap 397.65M
Revenue (ttm) 0.00
Net Income (ttm) -61.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.18
Volume 241,972
Avg Vol 2,024,286
Day's Range N/A - N/A
Shares Out 31.07M
Stochastic %K 21%
Beta 2.95
Analysts Strong Sell
Price Target $29.25

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 200 0412
Address:
650 Castro Street, Suite 450, Mountain View, United States
Iightning
Iightning Dec. 4 at 11:59 PM
1ightning® Premium Options Alert (Actionable) Ticker: $ANRO Contract: Dec 19 $12.5C Entry: 1.52 Exit: 2.37 Return: +55.16% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 7:38 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ANRO Contract: Dec 19 $12.5C Entry: 1.55 Exit: 2.62 Return: +69.34% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 3 at 10:41 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ANRO Contract: Dec 19 $10C Entry: 3.50 Exit: 6.33 Return: +80.81% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 2:04 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ANRO **Contract:** Dec 19 $15C **Entry:** 1.78 **Exit:** 3.52 **Return:** **+98.38% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
StreetwiseReports
StreetwiseReports Dec. 1 at 6:56 PM
Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive https://ow.ly/1Cpp50XAfJz Alto Neuroscience Inc. ($ANRO:NYSE) continues moving its clinical programs forward, receives regulatory clarity and raises US$50 million, during the past four months. Read on for analysts' thoughts on this biopharma.
0 · Reply
StreetwiseReports
StreetwiseReports Dec. 1 at 6:49 PM
Biotech Co.'s Q3/25 Progress on Lead Programs Steady https://ow.ly/s00f50XAftb Alto Neuroscience Inc.'s ($ANRO:NYSE) clinical execution and regulatory momentum advance the firm's biomarker-guided precision psychiatry pipeline, noted an H.C. Wainwright & Co. report.
0 · Reply
Ccperk
Ccperk Dec. 1 at 4:17 PM
$ANRO the market cap of this stock is just a little over 400 million. I’m no expert but I think a conservative prediction of the market cap should be a billion….800 million mkt cap yields a price of $25 to $26 👀. GL and not financial advice!
0 · Reply
brandoppsx
brandoppsx Nov. 30 at 10:55 PM
$BULL I love Webull as a platform... But I feel like the dumbest of fucks since I took out my small profit of maybe a couple hundred from $ANRO when it was still 3 bucks and moved it here... When I could have put everything there and made bank ..
1 · Reply
signaljumper
signaljumper Nov. 30 at 6:08 PM
$MIST free report with chart targets, you can find here: https://www.patreon.com/posts/mist-milestone-144741399?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link there you can find other reports with stocks that run over 50% since the report was released. as example $MLTX $ANRO
1 · Reply
MOOSEN
MOOSEN Nov. 26 at 9:09 PM
$ANRO HOLY FUCKING SPREAD.
0 · Reply
Latest News on ANRO
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Dec 3, 2025, 4:05 PM EST - 1 day ago

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026

Nov 28, 2025, 12:38 PM EST - 6 days ago

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:57 AM EST - 22 days ago

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience to Participate in Upcoming Investor Conferences

Oct 28, 2025, 7:34 AM EDT - 5 weeks ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Announces $50 Million Private Placement Financing

Oct 20, 2025, 7:03 AM EDT - 6 weeks ago

Alto Neuroscience Announces $50 Million Private Placement Financing

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Oct 20, 2025, 7:01 AM EDT - 6 weeks ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 8, 2025, 9:56 AM EDT - 2 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 2 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Oct 3, 2025, 7:34 AM EDT - 2 months ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Sep 13, 2025, 11:50 AM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Sep 9, 2025, 7:09 AM EDT - 3 months ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 28, 2025, 5:40 PM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 22, 2025, 10:15 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 18, 2025, 9:45 AM EDT - 3 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Aug 18, 2025, 8:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 4:10 PM EDT - 4 months ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 13, 2025, 8:03 AM EDT - 4 months ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

Aug 4, 2025, 2:46 PM EDT - 4 months ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jul 22, 2025, 6:25 PM EDT - 4 months ago

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Jun 30, 2025, 8:03 AM EDT - 5 months ago

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 26, 2025, 7:33 AM EDT - 5 months ago

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Jun 3, 2025, 6:03 AM EDT - 6 months ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 29, 2025, 8:03 AM EDT - 6 months ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 4:10 PM EDT - 7 months ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 28, 2025, 8:03 AM EDT - 7 months ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Apr 22, 2025, 8:03 AM EDT - 8 months ago

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 4:10 PM EDT - 9 months ago

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 9 months ago

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Feb 19, 2025, 8:03 AM EST - 10 months ago

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Feb 12, 2025, 8:03 AM EST - 10 months ago

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

Feb 2, 2025, 11:00 AM EST - 10 months ago

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

Iightning
Iightning Dec. 4 at 11:59 PM
1ightning® Premium Options Alert (Actionable) Ticker: $ANRO Contract: Dec 19 $12.5C Entry: 1.52 Exit: 2.37 Return: +55.16% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 7:38 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ANRO Contract: Dec 19 $12.5C Entry: 1.55 Exit: 2.62 Return: +69.34% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 3 at 10:41 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ANRO Contract: Dec 19 $10C Entry: 3.50 Exit: 6.33 Return: +80.81% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 2:04 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ANRO **Contract:** Dec 19 $15C **Entry:** 1.78 **Exit:** 3.52 **Return:** **+98.38% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
StreetwiseReports
StreetwiseReports Dec. 1 at 6:56 PM
Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive https://ow.ly/1Cpp50XAfJz Alto Neuroscience Inc. ($ANRO:NYSE) continues moving its clinical programs forward, receives regulatory clarity and raises US$50 million, during the past four months. Read on for analysts' thoughts on this biopharma.
0 · Reply
StreetwiseReports
StreetwiseReports Dec. 1 at 6:49 PM
Biotech Co.'s Q3/25 Progress on Lead Programs Steady https://ow.ly/s00f50XAftb Alto Neuroscience Inc.'s ($ANRO:NYSE) clinical execution and regulatory momentum advance the firm's biomarker-guided precision psychiatry pipeline, noted an H.C. Wainwright & Co. report.
0 · Reply
Ccperk
Ccperk Dec. 1 at 4:17 PM
$ANRO the market cap of this stock is just a little over 400 million. I’m no expert but I think a conservative prediction of the market cap should be a billion….800 million mkt cap yields a price of $25 to $26 👀. GL and not financial advice!
0 · Reply
brandoppsx
brandoppsx Nov. 30 at 10:55 PM
$BULL I love Webull as a platform... But I feel like the dumbest of fucks since I took out my small profit of maybe a couple hundred from $ANRO when it was still 3 bucks and moved it here... When I could have put everything there and made bank ..
1 · Reply
signaljumper
signaljumper Nov. 30 at 6:08 PM
$MIST free report with chart targets, you can find here: https://www.patreon.com/posts/mist-milestone-144741399?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link there you can find other reports with stocks that run over 50% since the report was released. as example $MLTX $ANRO
1 · Reply
MOOSEN
MOOSEN Nov. 26 at 9:09 PM
$ANRO HOLY FUCKING SPREAD.
0 · Reply
WycklyTrader
WycklyTrader Nov. 26 at 5:06 PM
$AMLX / $ANRO $GAP Fill $GME $PLUG : $ QNCX trend-reversal-base breakout momentum heading into 1Q2026 ph3 data announcement with multiple 'potential' gap fills.
0 · Reply
Iightning
Iightning Nov. 26 at 4:59 AM
1ightning® Options Trade Alert (Actionable) | Buy $ANRO Dec 19 $15 Call | Enter: $0.80 Exit: $1.30 | Profit: 62.58% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 3:07 PM
1ightning® Options Trade Alert (Actionable) | Buy $ANRO Dec 19 $15 Call | Enter: $0.80 Exit: $1.30 | Profit: 62.58% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 4:01 AM
1ightning® Options Trade Alert (Actionable) | Buy $ANRO Dec 19 $15 Call | Enter: $0.80 Exit: $1.30 | Profit: 62.58% ROI | https://1ightning.com
0 · Reply
MOOSEN
MOOSEN Nov. 25 at 12:40 AM
$ANRO STILL PEEPING.
0 · Reply
Iightning
Iightning Nov. 22 at 1:13 AM
1ightning® Options Trade Alert (Actionable) | Buy $ANRO Dec 19 $15 Call | Enter: $1.73 Exit: $3.33 | Profit: 92.92% ROI | https://1ightning.com
0 · Reply
Stef_DL
Stef_DL Nov. 21 at 7:06 PM
$ANRO She might just crawl out this hole. Go baby!
0 · Reply
Iightning
Iightning Nov. 21 at 4:35 AM
1ightning® Options Trade Alert (Actionable) | Buy $ANRO Dec 19 $15 Call | Enter: $1.73 Exit: $3.33 | Profit: 92.92% ROI | https://1ightning.com
0 · Reply
MOOSEN
MOOSEN Nov. 21 at 12:57 AM
$ANRO EYES ON IT.
0 · Reply
Iightning
Iightning Nov. 20 at 2:12 AM
1ightning® Options Trade Alert (Actionable) | Buy $ANRO Dec 19 $15 Call | Enter: $1.73 Exit: $3.33 | Profit: 92.92% ROI | https://1ightning.com
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 19 at 8:36 PM
$ANRO given u $CYTH movement code for several months which is $RFL
0 · Reply
MOOSEN
MOOSEN Nov. 19 at 8:30 PM
$ANRO SHEESH.
0 · Reply